Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.

Erhardt A, Kolligs F, Dollinger M, Schott E, Wege H, Bitzer M, Gog C, Lammert F, Schuchmann M, Walter C, Blondin D, Ohmann C, Häussinger D.

Cancer Chemother Pharmacol. 2014 Nov;74(5):947-54. doi: 10.1007/s00280-014-2568-8. Epub 2014 Aug 31.

PMID:
25173458
2.

Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.

Lee JE, Bae SH, Choi JY, Yoon SK, You YK, Lee MA.

World J Gastroenterol. 2014 Jan 7;20(1):235-41. doi: 10.3748/wjg.v20.i1.235.

3.

The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.

Cho JY, Paik YH, Park HC, Yu JI, Sohn W, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.

Liver Int. 2014 May;34(5):795-801. doi: 10.1111/liv.12445. Epub 2014 Jan 12.

PMID:
24350564
4.

Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial.

Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY, Chao Y.

Int J Cancer. 2013 May 15;132(10):2448-58. doi: 10.1002/ijc.27925. Epub 2012 Nov 28.

5.

Treatment with sorafenib in advanced thyroid cancer - a case report.

Krajewska J, Olczyk T, Roskosz J, Paliczk-Cieślik E, Smietana AK, Kaczmarek-Borowska B, Jarząb B.

Endokrynol Pol. 2010 Sep-Oct;61(5):492-6.

PMID:
21049464

Supplemental Content

Loading ...
Support Center